Novartis Investigative Site

Bordeaux, Aquitaine 33076

0 studies enrolling now · 3 studies all time

What they study most

Graft-versus-host Disease (GVHD), Medulloblastoma, Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

Studies at this site

• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) — Completed
• Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. — Completed
• A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) — Completed